Cellceutix Corp. has filed an application with the FDA requesting Orphan Drug designation for its novel antibiotic Brilacidin-OM as a drug candidate for the prevention of radiation or chemotherapy-induced oral mucositis in head and neck cancer. Brilacidin-OM is a defensin mimetic that has antibacterial, anti-biofilm and anti-inflammatory properties. The company is planning a Phase II trial of Brilacidin-OM to meet an area of great unmet medical need for cancer patients that suffer from the cond...